High expression of enhancer of zeste homologue 2 indicates poor prognosis in patients with soft tissue sarcomas

Molecular Medicine Reports

Volumn 1, Issue 5, 2008, Pages 633-639

  Yamaga, Kensaku ^a   Osaki, Mitsuhiko ^a,b   Kidani, Kazunori ^a   Shomori, Kohei ^a   Yoshida, Haruhiko ^a   Ito, Hisao ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

EZH2; Ki 67; Prognostic factor; Soft tissue sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; ENHANCER OF ZESTE HOMOLOGUE 2; KI 67 ANTIGEN; POLYCOMB GROUP PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER RADIOTHERAPY; CHILD; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PROGNOSIS; SOFT TISSUE SARCOMA; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 69449103976     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000004     Document Type: Article

References (47)

1. Stefanovski PD, Bidoli E, De Paoli A, et al: Prognostic factors in soft tissue sarcomas: a study of 395 patients. Eur J Surg Oncol 28: 153-164, 2002. (Pubitemid 35023657)
2. Lewis JJ, Leung D, Casper ES, Woodruff J, Hajdu SI and Brennan MF: Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma. Arch Surg 134: 190-194, 1999. (Pubitemid 29088973)
3. Levine EA: Prognostic factors in soft tissue sarcoma. Semin Surg Oncol 17: 23-32, 1999. (Pubitemid 29305113)
4. Ottaiano A, De Chiara A, Fazioli F, et al: Biological prognostic factors in adult soft tissue sarcomas. Anticancer Res 25: 4519-4526, 2005. (Pubitemid 41729506)
5. Engellau J, Bendahl PO, Persson A, et al: Improved prognostication in soft tissue sarcoma: independent information from vascular invasion, necrosis, growth pattern, and immunostaining using whole-tumor sections and tissue microarrays. Hum Pathol 36: 994-1002, 2005. (Pubitemid 41253386)
6. Engellau J: Prognostic factors in soft tissue sarcoma. Tissue microarray for immunostaining, the importance of whole-tumor sections and time-dependence. Acta Orthop Scand 75 (Suppl): 2 p preceding table, 2004.
7. Hasegawa T, Yokoyama R, Lee YH, Shimoda T, Beppu Y and Hirohashi S: Prognostic relevance of a histological grading system using MIB-1 for adult soft-tissue sarcoma. Oncology 58: 66-74, 2000. (Pubitemid 30045312)
8. Tomita Y, Morooka T, Hoshida Y, et al: Reassessment of the 1993 Osaka grading system for localized soft tissue sarcoma in Japan. Anticancer Res 26: 4665-4669, 2006.
9. Hasegawa T, Yamamoto S, Yokoyama R, Umeda T, Matsuno Y and Hirohashi S: Prognostic significance of grading and staging systems using MIB-1 score in adult patients with soft tissue sarcoma of the extremities and trunk. Cancer 95: 843-851, 2002. (Pubitemid 34839677)
10. Jensen V, Sorensen FB, Bentzen SM, et al: Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immuno-histological study including 216 soft tissue sarcomas. Histopathology 32: 536-546, 1998. (Pubitemid 28277554)
11. Kroese MC, Rutgers DH, Wils IS, van Unnik JA and Roholl PJ: The relevance of the DNA index and proliferation rate in the grading of benign and malignant soft tissue tumors. Cancer 65: 1782-1788, 1990.
12. Endo M, Tateishi U, Seki K, et al: Prognostic implications of glucose transporter protein-1 (glut-1) overexpression in bone and soft-tissue sarcomas. Jpn J Clin Oncol 37: 955-960, 2007. (Pubitemid 351176488)
13. Huuhtanen RL, Blomqvist CP, Bohling TO, et al: Expression of cyclin A in soft tissue sarcomas correlates with tumor aggressiveness. Cancer Res 59: 2885-2890, 1999. (Pubitemid 29283127)
14. Musella M, Fazioli F, Lombardi S, et al: Assessment of cyclin D1 overexpression as a prognostic factor in soft tissue sarcomas: role of laparoscopy and core needle biopsy. Surg Endosc 19: 1120-1124, 2005. (Pubitemid 41494832)
15. Ch'ng E, Tomita Y, Zhang B, et al: Prognostic significance of CD100 expression in soft tissue sarcoma. Cancer 110: 164-172, 2007. (Pubitemid 46986429)
16. Shintani K, Matsumine A, Kusuzaki K, et al: Expression of hypoxia-inducible factor (HIF)-1alpha as a biomarker of outcome in soft-tissue sarcomas. Virchows Arch 449: 673-681, 2006. (Pubitemid 44832639)
17. Sato O, Wada T, Kawai A, et al: Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases. Cancer 103: 1881-1890, 2005.
18. Ahlen J, Wejde J, Brosjo O, et al: Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma. Clin Cancer Res 11: 206-216, 2005. (Pubitemid 40075797)
19. Tomita Y, Morooka T, Hoshida Y, et al: Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin Cancer Res 12: 3070-3077, 2006. (Pubitemid 43837353)
20. Weng WH, Ahlen J, Astrom K, Lui WO and Larsson C: Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res 11: 6198-6204, 2005. (Pubitemid 41262948)
21. Peiper M, Sato T, Zurakowski D, et al: CD44s expression is associated with improved survival in soft tissue sarcoma. Anticancer Res 24: 1053-1056, 2004. (Pubitemid 38624937)
22. Takahiro T, Shinichi K and Toshimitsu S: Expression of fatty acid synthase as a prognostic indicator in soft tissue sarcomas. Clin Cancer Res 9: 2204-2212, 2003. (Pubitemid 36687644)
23. Taubert HW, Bartel F, Kappler M, et al: Reduced expression of hMSH2 protein is correlated to poor survival for soft tissue sarcoma patients. Cancer 97: 2273-2278, 2003. (Pubitemid 36444072)
24. Kappler M, Kotzsch M, Bartel F, et al: Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clin Cancer Res 9: 1098-1104, 2003. (Pubitemid 36323717)
25. Yamashita H, Osaki M, Ardyanto TD, Osaki M, Yoshida H and Ito H: Cyclooxygenase-2 in human malignant fibrous histiocytoma: correlations with intratumoral microvessel density, expression of vascular endothelial growth factor and thymidine phosphorylase. Int J Mol Med 14: 565-570, 2004.
26. Sato T, Peiper M, Heinecke A, et al: Expression of HER2/neu does not correlate with survival in soft tissue sarcoma. Onkologie 26: 268-271, 2003. (Pubitemid 36831216)
27. Osaki M, Osaki M, Yamashita H, Shomori K, Yoshida H and Ito H: Expression of minichromosome maintenance-2 in human malignant fibrous histiocytomas: correlations with Ki-67 and P53 expression, and apoptosis. Int J Mol Med 10: 161-168, 2002.
28. Yu J, Yu J, Rhodes DR, et al: A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 67: 10657-10663, 2007. (Pubitemid 350145890)
29. Chen H, Rossier C and Antonarakis SE: Cloning of a human homolog of the Drosophila enhancer of zeste gene (EZH2) that maps to chromosome 21q22.2. Genomics 38: 30-37, 1996. (Pubitemid 26423910)
30. Varambally S, Dhanasekaran SM, Zhou M, et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629, 2002.
31. Kleer CG, Cao Q, Varambally S, et al: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100: 11606-11611, 2003. (Pubitemid 37205983)
32. Raaphorst FM, van Kemenade FJ, Blokzijl T, et al: Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol 157: 709-715, 2000. (Pubitemid 32109362)
33. Ding L and Kleer CG: Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast. Cancer Res 66: 9352-9355, 2006. (Pubitemid 44623628)
34. Bachmann IM, Halvorsen OJ, Collett K, et al: EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate and breast. J Clin Oncol 24: 268-273, 2006. (Pubitemid 46622055)
35. Arisan S, Buyuktuncer ED, Palavan-Unsal N, Caskurlu T, Cakir OO and Ergenekon E: Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol Int 75: 252-257, 2005. (Pubitemid 41433876)
36. Weikert S, Christoph F, Kollermann J, et al: Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med 16: 349-353, 2005.
37. Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS and Gudas LJ: Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 11: 8570-8576, 2005. (Pubitemid 43005902)
38. Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K and Yokozaki H: Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 97: 484-491, 2006. (Pubitemid 43811589)
39. Mattioli E, Vogiatzi P, Sun A, et al: Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer. J Cell Physiol 210: 183-191, 2007.
40. Raaphorst FM, Meijer CJ, Fieret E, et al: Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 5: 481-488, 2003. (Pubitemid 38045085)
41. Visser HP, Gunster MJ, Kluin-Nelemans HC, et al: The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 112: 950-958, 2001.
42. Fletcher CDM, Unni KK and Mertens F: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft tissue and Bone. IARC Press, Lyon, 2002.
43. Guillou L, Coindre JM, Bonichon F, et al: Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 15: 350-362, 1997. (Pubitemid 27020593)
44. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N and Rotter V: Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 23: 5759-5769, 2004. (Pubitemid 39093021)
45. Beke L, Nuytten M, van Eynde A, Beullens M and Bollen M: The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Oncogene 26: 4590-4595, 2007. (Pubitemid 47037047)
46. Gerdes J, Schwab U, Lemke H and Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13-20, 1983. (Pubitemid 13179545)
47. Coindre JM: Grading of soft tissue sarcomas: review and update. Arch Pathol Lab Med 130: 1448-1453, 2006. (Pubitemid 44520711)